HSD3B1 and Familial prostate cancer: Recent studies have demonstrated that genetic polymorphism in HSD3B1 is associated with oncological outcome among residents in the United States treated with ADT, where men carrying variant alleles showed worse prognosis.11,12,13 Thus, genetic variation in HSD3B1 (1245C) genotype is a promising predictive biomarker of positive ADT response among men with prostate cancer.